Parallel determination of neuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers

L. Cindolo, M. Cantile, R. Franco, P. Chiodini, G. Schiavo, I. Forte, I. Zlobec, L. Salzano, G. Botti, S. Gidaro, L. Terracciano, C. Cillo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Neuroendocrine differentiation is a hallmark of prostate cancer. The aim of our study was the detection of the parallel expression of neuroendocrine related markers using a prostate tissue microarray (TMA). Materials and Methods: Our study was aimed at detecting the parallel expression of NeuroD1, Chromogranin-A (ChrA), Androgen Receptor (AR) and Ki-67 by immunohistochemistry on prostate cancer tissue microarray. The data was analyzed using SAS version 8.2 (SAS Inc, Cary, NC). The relationships between NeuroD1, ChrA and AR expressions and patients' characteristics were investigated by multivariate logistic regression analysis. Progression and Overall Survival (OS) distributions were calculated using Kaplan-Meier method. Results: Tissue reactivity for NeuroD1, ChrA and AR concerned 73%, 49% and 77% of the available cases, respectively. Regarding overall survival, there were 87 deaths and 295 patients alive/censored (6 years of median follow-up). Seventy-seven disease progressions occurred at the median follow-up 5.4y. A significant correlation between NeuroD1, ChrA and AR expression was observed (p <0.001 and p <0.03, respectively). Additionally, ChrA was strongly associated in multivariate analysis to Gleason score and Ki67 expression (p <0.009 and p <0.0052, respectively). Survival analysis showed no association between markers neither for overall nor for cancer-specific survival. Conclusions: The results highlight that NeuroD1, Chromogranin-A and Androgen Receptor are strongly associated, however their expression does not correlate with overall survival or disease progression.

Original languageEnglish
Pages (from-to)57-66
Number of pages10
JournalInternational Braz J Urol
Volume37
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Chromogranin A
Androgen Receptors
Prostatic Neoplasms
Survival
Disease Progression
Neoplasm Grading
Survival Analysis
Prostate
Multivariate Analysis
Logistic Models
Immunohistochemistry
Regression Analysis
Neoplasms

Keywords

  • Androgen prognosis
  • Chromogranin A
  • Ki-67 antigen
  • NeuroD1 protein
  • Neuroendocrine cells
  • Prostatic neoplasms
  • Receptors

ASJC Scopus subject areas

  • Urology

Cite this

Parallel determination of neuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers. / Cindolo, L.; Cantile, M.; Franco, R.; Chiodini, P.; Schiavo, G.; Forte, I.; Zlobec, I.; Salzano, L.; Botti, G.; Gidaro, S.; Terracciano, L.; Cillo, C.

In: International Braz J Urol, Vol. 37, No. 1, 01.2011, p. 57-66.

Research output: Contribution to journalArticle

Cindolo, L. ; Cantile, M. ; Franco, R. ; Chiodini, P. ; Schiavo, G. ; Forte, I. ; Zlobec, I. ; Salzano, L. ; Botti, G. ; Gidaro, S. ; Terracciano, L. ; Cillo, C. / Parallel determination of neuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers. In: International Braz J Urol. 2011 ; Vol. 37, No. 1. pp. 57-66.
@article{87f6e02776694498aaba4cb1c2fe9f84,
title = "Parallel determination of neuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers",
abstract = "Purpose: Neuroendocrine differentiation is a hallmark of prostate cancer. The aim of our study was the detection of the parallel expression of neuroendocrine related markers using a prostate tissue microarray (TMA). Materials and Methods: Our study was aimed at detecting the parallel expression of NeuroD1, Chromogranin-A (ChrA), Androgen Receptor (AR) and Ki-67 by immunohistochemistry on prostate cancer tissue microarray. The data was analyzed using SAS version 8.2 (SAS Inc, Cary, NC). The relationships between NeuroD1, ChrA and AR expressions and patients' characteristics were investigated by multivariate logistic regression analysis. Progression and Overall Survival (OS) distributions were calculated using Kaplan-Meier method. Results: Tissue reactivity for NeuroD1, ChrA and AR concerned 73{\%}, 49{\%} and 77{\%} of the available cases, respectively. Regarding overall survival, there were 87 deaths and 295 patients alive/censored (6 years of median follow-up). Seventy-seven disease progressions occurred at the median follow-up 5.4y. A significant correlation between NeuroD1, ChrA and AR expression was observed (p <0.001 and p <0.03, respectively). Additionally, ChrA was strongly associated in multivariate analysis to Gleason score and Ki67 expression (p <0.009 and p <0.0052, respectively). Survival analysis showed no association between markers neither for overall nor for cancer-specific survival. Conclusions: The results highlight that NeuroD1, Chromogranin-A and Androgen Receptor are strongly associated, however their expression does not correlate with overall survival or disease progression.",
keywords = "Androgen prognosis, Chromogranin A, Ki-67 antigen, NeuroD1 protein, Neuroendocrine cells, Prostatic neoplasms, Receptors",
author = "L. Cindolo and M. Cantile and R. Franco and P. Chiodini and G. Schiavo and I. Forte and I. Zlobec and L. Salzano and G. Botti and S. Gidaro and L. Terracciano and C. Cillo",
year = "2011",
month = "1",
doi = "10.1590/S1677-55382011000100008",
language = "English",
volume = "37",
pages = "57--66",
journal = "International braz j urol : official journal of the Brazilian Society of Urology",
issn = "1677-5538",
publisher = "Brazilian Society of Urology",
number = "1",

}

TY - JOUR

T1 - Parallel determination of neuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers

AU - Cindolo, L.

AU - Cantile, M.

AU - Franco, R.

AU - Chiodini, P.

AU - Schiavo, G.

AU - Forte, I.

AU - Zlobec, I.

AU - Salzano, L.

AU - Botti, G.

AU - Gidaro, S.

AU - Terracciano, L.

AU - Cillo, C.

PY - 2011/1

Y1 - 2011/1

N2 - Purpose: Neuroendocrine differentiation is a hallmark of prostate cancer. The aim of our study was the detection of the parallel expression of neuroendocrine related markers using a prostate tissue microarray (TMA). Materials and Methods: Our study was aimed at detecting the parallel expression of NeuroD1, Chromogranin-A (ChrA), Androgen Receptor (AR) and Ki-67 by immunohistochemistry on prostate cancer tissue microarray. The data was analyzed using SAS version 8.2 (SAS Inc, Cary, NC). The relationships between NeuroD1, ChrA and AR expressions and patients' characteristics were investigated by multivariate logistic regression analysis. Progression and Overall Survival (OS) distributions were calculated using Kaplan-Meier method. Results: Tissue reactivity for NeuroD1, ChrA and AR concerned 73%, 49% and 77% of the available cases, respectively. Regarding overall survival, there were 87 deaths and 295 patients alive/censored (6 years of median follow-up). Seventy-seven disease progressions occurred at the median follow-up 5.4y. A significant correlation between NeuroD1, ChrA and AR expression was observed (p <0.001 and p <0.03, respectively). Additionally, ChrA was strongly associated in multivariate analysis to Gleason score and Ki67 expression (p <0.009 and p <0.0052, respectively). Survival analysis showed no association between markers neither for overall nor for cancer-specific survival. Conclusions: The results highlight that NeuroD1, Chromogranin-A and Androgen Receptor are strongly associated, however their expression does not correlate with overall survival or disease progression.

AB - Purpose: Neuroendocrine differentiation is a hallmark of prostate cancer. The aim of our study was the detection of the parallel expression of neuroendocrine related markers using a prostate tissue microarray (TMA). Materials and Methods: Our study was aimed at detecting the parallel expression of NeuroD1, Chromogranin-A (ChrA), Androgen Receptor (AR) and Ki-67 by immunohistochemistry on prostate cancer tissue microarray. The data was analyzed using SAS version 8.2 (SAS Inc, Cary, NC). The relationships between NeuroD1, ChrA and AR expressions and patients' characteristics were investigated by multivariate logistic regression analysis. Progression and Overall Survival (OS) distributions were calculated using Kaplan-Meier method. Results: Tissue reactivity for NeuroD1, ChrA and AR concerned 73%, 49% and 77% of the available cases, respectively. Regarding overall survival, there were 87 deaths and 295 patients alive/censored (6 years of median follow-up). Seventy-seven disease progressions occurred at the median follow-up 5.4y. A significant correlation between NeuroD1, ChrA and AR expression was observed (p <0.001 and p <0.03, respectively). Additionally, ChrA was strongly associated in multivariate analysis to Gleason score and Ki67 expression (p <0.009 and p <0.0052, respectively). Survival analysis showed no association between markers neither for overall nor for cancer-specific survival. Conclusions: The results highlight that NeuroD1, Chromogranin-A and Androgen Receptor are strongly associated, however their expression does not correlate with overall survival or disease progression.

KW - Androgen prognosis

KW - Chromogranin A

KW - Ki-67 antigen

KW - NeuroD1 protein

KW - Neuroendocrine cells

KW - Prostatic neoplasms

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=79955892655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955892655&partnerID=8YFLogxK

U2 - 10.1590/S1677-55382011000100008

DO - 10.1590/S1677-55382011000100008

M3 - Article

C2 - 21385481

AN - SCOPUS:79955892655

VL - 37

SP - 57

EP - 66

JO - International braz j urol : official journal of the Brazilian Society of Urology

JF - International braz j urol : official journal of the Brazilian Society of Urology

SN - 1677-5538

IS - 1

ER -